In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Business Case For Post-Grant Patent Review

Executive Summary

Counsels’ view of what inter parte reviews and other new procedures introduced by the America Invents Act mean to the biopharma industry.

You may also be interested in...



The Patent Trolls Are Coming...To Medtech

For years medical device makers have largely avoided one of the technology world’s biggest headaches: patent “troll” litigation, but that’s about to change. What medtech needs to do to fight the trolls.

Patent Trolls Eye Biotech Firms; New PTO Proceedings Are ‘Game Changer’

Patent review proceedings established by America Invents Act may become ‘close second’ to ANDA litigation as way to invalidate patents; industry calls for changes as patent claims are routinely struck down.

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel